NASDAQ:MOTSMotus GI Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Motus GI Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.23 -0.02 (-1.60 %) (As of 08/10/2020 12:09 PM ET) Add Compare Share Today's Range$1.20Now: $1.23▼$1.2850-Day Range$1.18MA: $1.26▼$1.4252-Week Range$0.46Now: $1.23▼$2.99Volume40,292 shsAverage Volume48,390 shsMarket Capitalization$35.50 millionP/E RatioN/ADividend YieldN/ABeta2.99 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMotus GI has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Motus GI has a potential upside of 224.1% from its current price of $1.23.Amount of Analyst CoverageMotus GI has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesMotus GI has received 145 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMotus GI has received 143 “underperform” votes. (Add your “underperform” vote.)Community SentimentMotus GI has received 50.35% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Motus GI and other stocks. Vote “Outperform” if you believe MOTS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MOTS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMotus GI does not currently pay a dividend.Dividend GrowthMotus GI does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Motus GI insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.13% of the stock of Motus GI is held by insiders.Percentage Held by Institutions38.62% of the stock of Motus GI is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Motus GI are expected to grow in the coming year, from ($0.66) to ($0.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Motus GI is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Motus GI is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMotus GI has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MOTS Previous Symbol CUSIPN/A CIK1686850 Webwww.motusgi.com Phone954-541-8000Debt Debt-to-Equity Ratio0.06 Current Ratio2.15 Quick Ratio2.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales322.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.92Profitability EPS (Most Recent Fiscal Year)($0.92) Net Income$-23,090,000.00 Net Margins-17,405.97% Return on Equity-148.97% Return on Assets-91.63%Miscellaneous Employees44 Outstanding Shares28,860,000Market Cap$35.50 million Next Earnings Date8/11/2020 (Confirmed) OptionableNot Optionable $1.23 -0.02 (-1.60 %) (As of 08/10/2020 12:09 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MOTS News and Ratings via Email Sign-up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter. Motus GI (NASDAQ:MOTS) Frequently Asked Questions How has Motus GI's stock been impacted by COVID-19 (Coronavirus)? Motus GI's stock was trading at $1.04 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MOTS shares have increased by 18.3% and is now trading at $1.23. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Motus GI? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Motus GI. When is Motus GI's next earnings date? Motus GI is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Motus GI. How can I listen to Motus GI's earnings call? Motus GI will be holding an earnings conference call on Tuesday, August 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Motus GI's earnings last quarter? Motus GI Holdings Inc (NASDAQ:MOTS) issued its quarterly earnings data on Thursday, May, 14th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.01. The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.15 million. Motus GI had a negative return on equity of 148.97% and a negative net margin of 17,405.97%. View Motus GI's earnings history. What price target have analysts set for MOTS? 3 brokers have issued 12-month price targets for Motus GI's shares. Their forecasts range from $3.00 to $7.00. On average, they expect Motus GI's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price. View analysts' price targets for Motus GI. Has Motus GI been receiving favorable news coverage? News articles about MOTS stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Motus GI earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Motus GI. Who are some of Motus GI's key competitors? Some companies that are related to Motus GI include Restoration Robotics (HAIR), Soliton (SOLY), Venus Concept (VERO), PAVmed (PAVM), BeyondAirInc . (XAIR), Spectral Medical (EDTXF), Pro-Dex (PDEX), SANUWAVE Health (SNWV), Nephros (NEPH), Neuronetics (STIM), BRAINSWAY LTD/S (BWAY), Titan Medical (TMDI), Nephros (NEPHD), DarioHealth (DRIO) and AIT Therapeutics (AITB). View all competitors. What other stocks do shareholders of Motus GI own? Based on aggregate information from My MarketBeat watchlists, some companies that other Motus GI investors own include Canopy Growth (CGC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), AT&T (T), Verizon Communications (VZ), Zynerba Pharmaceuticals (ZYNE), Heron Therapeutics (HRTX) and Netflix (NFLX). Who are Motus GI's key executives? Motus GI's management team includes the following people: Mr. Timothy P. Moran, CEO & Director (Age 47)Mr. Mark Pomeranz, Pres, COO & Director (Age 58)Mr. Andrew Lawrence Taylor, Chief Financial Officer (Age 48) When did Motus GI IPO? (MOTS) raised $21 million in an IPO on Wednesday, February 14th 2018. The company issued 3,500,000 shares at $5.00-$7.00 per share. Piper Jaffray acted as the underwriter for the IPO and Oppenheimer & Co. was co-manager. What is Motus GI's stock symbol? Motus GI trades on the NASDAQ under the ticker symbol "MOTS." How do I buy shares of Motus GI? Shares of MOTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Motus GI's stock price today? One share of MOTS stock can currently be purchased for approximately $1.23. How big of a company is Motus GI? Motus GI has a market capitalization of $35.50 million and generates $110,000.00 in revenue each year. The company earns $-23,090,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. Motus GI employs 44 workers across the globe. What is Motus GI's official website? The official website for Motus GI is www.motusgi.com. How can I contact Motus GI? Motus GI's mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The company can be reached via phone at 954-541-8000 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
